BELGIUM - Peakadilly receives EUR 6m series-A financing

LSP has invested EUR 3m in the company and will appoint Nick McCooke as CEO and Martijn Kleijwegt as non-executive director. Johnson & Johnson Development Corporation has co-led the transaction, and will appoint Zeev Zehavi as non-executive director. Coincident with the funding, Peakadilly founder, VIB (Flanders Interuniversity Institute of Biotechnology), completed the contribution in kind to Peakadilly of the core technology underpinning MASStermind.

Peakadilly was founded in late 2004 to exploit the protein biomarker discovery technology, which has been developed by a research group led by Prof Joel Vandekerckhove at VIB and the University of Ghent, Belgium. The current financing will be used to increase the capacity of Peakadilly’s protein biomarker discovery operation based on its proprietary MASStermind™ technology, enabling it to expand its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux